Novartis reports positive data for second fingolimod Phase III study in MS - update
02 October 2009
Katie McQue
Novartis's oral multiple sclerosis therapy fingolimod (FTY-720) has met the primary endpoint of its second Phase III trial, FREEDOMS, in which it reduced the annual relapse rate (ARR) in relapsing-remitting MS 54% better than placebo.
The safety data showed that no increase in cancers was associated...
Please Login to read the full article.
02 October 2009
Katie McQue
The safety data showed that no increase in cancers was associated...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
